Fig 1. CONSORT diagram (patient disposition). HER3, human epidermal growth factor receptor 3; PD, progressive disease. Fig 2. Kaplan-Meier plots of (A) PFS and (B) DOR, both by BICR per RECIST 1.1.

Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors A total of 59 patients were ...

Researchers are hopeful the combination could become the “new go-to option” for women with PIK3CA-mutated hormone receptor ...

Artificial intelligence (AI)-assisted training improves pathologist accuracy in human epidermal growth factor receptor 2 ...

US FDA grants priority review status to Bayer’s sevabertinib to treat patients with HER2-mutant non-small cell lung cancer: Berlin Friday, May 30, 2025, 16:00 Hrs [IST] Bayer an ...

EMA committee recommends approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer: Basel Monday, May 26, 2025, 12:00 Hrs [IST] Roche an ...

Bayer announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's new drug application (NDA) and granted Priority Review designation for the investigational compound ...

Basel: Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

CHICAGO -- Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received ...

Berlin: Bayer has received Priority Review status from the US Food and Drug Administration (FDA) for the investigational ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

Detailed price information for Olema Pharmaceuticals Inc (OLMA-Q) from The Globe and Mail including charting and trades.